Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-26T16:07:40.097Z Has data issue: false hasContentIssue false
  • English
  • Français

Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis

Published online by Cambridge University Press:  21 November 2013

T. Kishi ,
H. Y. Meltzer ,
Y. Matsuda  and
N. Iwata
T. Kishi*
Affiliation:
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
H. Y. Meltzer
Affiliation:
Division of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Y. Matsuda
Affiliation:
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
N. Iwata
Affiliation:
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan
*
*Address for correspondence: T. Kishi, M.D., Ph.D., Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

A meta-analysis of the serotonin1A (5-HT1A) receptor partial agonist of the azapirone class as an anxiolytic drug for the treatment of major depressive disorder (MDD) has not previously been reported.

Method

We carried out a systematic review of the literature available in PubMed, the Cochrane Library database and PsycINFO up to 12 October 2013, and conducted a meta-analysis of randomized controlled trials (RCTs) comparing 5-HT1A agonists with placebo and RCTs of 5-HT1A agonist augmentation therapies for MDD treatment. We calculated the risk ratio (RR), number needed to treat (NNT)/number needed to harm (NNH) and 95% confidence intervals (CIs).

Results

Fifteen RCTs comparing 5-HT1A agonists with placebo (total n = 2469, four studies with buspirone, seven with gepirone, three with ipsapirone and one with zalospirone) were identified. Pooled 5-HT1A agonists had significantly more responders (RR 0.74, 95% CI 0.65–083, p < 0.00001, NNT = 6, 12 trials, n = 1816) than placebo. Pooled 5-HT1A agonists were superior to placebo in discontinuation due to inefficacy (RR 0.49, p = 0.02, NNH = 16, p = 0.03, 10 trials, n = 1494) but were inferior to placebo in discontinuation due to side-effects (RR 1.88, p < 0.0001, NNH = 17, p = 0.001, 13 trials, n = 2196). However, all-cause discontinuation was similar in both groups (RR 0.99, p = 0.85, 14 trials, n = 2402). Four 5-HT1A agonist augmentation studies were identified (total n = 365, three buspirone studies and one tandospirone study). There were no statistically significant effects of 5-HT1A agonist augmentation therapies on response rate (RR 0.98, p = 0.85, four trials, n = 341). 5-HT1A agonist-related side-effects including gastrointestinal symptoms, dizziness, insomnia, palpitation, paresthesia and sweating were greater than with placebo (p < 0.00001 to p = 0.03).

Conclusions

Our results suggest that 5-HT1A agonist has a more beneficial effect on MDD than placebo, but has several side-effects.

Keywords

Buspironegepironeipsapironemajor depressive disorder; meta-analysisserotonin1A receptor partial agonistzalospirone
Type
Review Article
Information
Psychological Medicine , Volume 44 , Issue 11 , August 2014 , pp. 2255 - 2269
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angst, J (1998). Sexual problems in healthy and depressed persons. International Clinical Psychopharmacology 13 (Suppl. 6), S1–S4.CrossRefGoogle ScholarPubMed
Appelberg, BG, Syvalahti, EK, Koskinen, TE, Mehtonen, OP, Muhonen, TT, Naukkarinen, HH (2001). Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. Journal of Clinical Psychiatry 62, 448–452.CrossRefGoogle ScholarPubMed
Aznar, S, Qian, Z, Shah, R, Rahbek, B, Knudsen, GM (2003). The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Research 959, 58–67.CrossRefGoogle ScholarPubMed
Bielski, RJ, Cunningham, L, Horrigan, JP, Londborg, PD, Smith, WT, Weiss, K (2008). Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. Journal of Clinical Psychiatry 69, 571–577.CrossRefGoogle ScholarPubMed
Bonierbale, M, Lancon, C, Tignol, J (2003). The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Current Medical Research and Opinion 19, 114–124.CrossRefGoogle ScholarPubMed
Cohn, LD, Becker, BJ (2003). How meta-analysis increases statistical power. Psychological Methods 8, 243–253.CrossRefGoogle ScholarPubMed
DerSimonian, R, Laird, N (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177–188.CrossRefGoogle ScholarPubMed
Drago, A, Crisafulli, C, Sidoti, A, Serretti, A (2011). The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Progress in Neurobiology 94, 418–460.CrossRefGoogle ScholarPubMed
Fabre, LF (1990). Buspirone in the management of major depression: a placebo-controlled comparison. Journal of Clinical Psychiatry 51 (Suppl.), 55–61.Google ScholarPubMed
Fabre, LF, Brown, CS, Smith, LC, Derogatis, LR (2011 a). Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. Journal of Sexual Medicine 8, 1411–1419.CrossRefGoogle ScholarPubMed
Fabre, LF, Clayton, AH, Smith, LC, Goldstein, I, Derogatis, LR (2012). The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men. Journal of Sexual Medicine 9, 821–829.CrossRefGoogle ScholarPubMed
Fabre, LF, Smith, LC, DeRogatis, LR (2011 b). Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain – a post hoc analysis. Journal of Sexual Medicine 8, 2569–2581.CrossRefGoogle ScholarPubMed
Fava, MT, Tarqum, SD, Nierenberg, AA, Bleicher, LS, Carter, TA, Wedel, PC, Hen, R, Gage, FH, Barlow, C (2012). An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery. Journal of Psychiatric Research 46, 1553–1563.CrossRefGoogle ScholarPubMed
Feiger, AD (1996). A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacology Bulletin 32, 659–665.Google ScholarPubMed
Feiger, AD, Heiser, JF, Shrivastava, RK, Weiss, KJ, Smith, WT, Sitsen, JM, Gibertini, M (2003). Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. Journal of Clinical Psychiatry 64, 243–249.CrossRefGoogle ScholarPubMed
Guy, W, Bonato, RR (1970). Manual for the ECDEU Assessment Battery, 2nd edn. National Institute of Mental Health: Chevy Chase, MD.Google Scholar
Hamilton, M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 23, 56–62.CrossRefGoogle ScholarPubMed
Heller, AH, Beneke, M, Kuemmel, B, Spencer, D, Kurtz, NM (1990). Ipsapirone: evidence for efficacy in depression. Psychopharmacology Bulletin 26, 219–222.Google ScholarPubMed
Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG (2003). Measuring inconsistency in meta-analyses. British Medical Journal 327, 557–560.CrossRefGoogle ScholarPubMed
Hindmarch, I (2002). Beyond the monoamine hypothesis: mechanisms, molecules and methods. European Psychiatry 17 (Suppl. 3), 294–299.CrossRefGoogle ScholarPubMed
Jenkins, SW, Robinson, DS, Fabre, LF Jr., Andary, JJ, Messina, ME, Reich, LA (1990). Gepirone in the treatment of major depression. Journal of Clinical Psychopharmacology 10, 77S–85S.CrossRefGoogle ScholarPubMed
Kato, T (2007). Molecular genetics of bipolar disorder and depression. Psychiatry and Clinical Neurosciences 61, 3–19.CrossRefGoogle ScholarPubMed
Kishi, T, Yoshimura, R, Fukuo, Y, Okochi, T, Matsunaga, S, Umene-Nakano, W, Nakamura, J, Serretti, A, Correll, CU, Kane, JM, Iwata, N (2013). The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience 263, 105–118.CrossRefGoogle ScholarPubMed
Landen, M, Bjorling, G, Agren, H, Fahlen, T (1998). A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. Journal of Clinical Psychiatry 59, 664–668.CrossRefGoogle ScholarPubMed
Lapierre, YD, Silverstone, P, Reesal, RT, Saxena, B, Turner, P, Bakish, D, Plamondon, J, Vincent, PM, Remick, RA, Kroft, C, Payeur, R, Rosales, D, Lam, R, Bologa, M (1998). A Canadian multicenter study of three fixed doses of controlled-release ipsapirone in outpatients with moderate to severe major depression. Journal of Clinical Psychopharmacology 18, 268–273.CrossRefGoogle ScholarPubMed
Le Francois, B, Czesak, M, Steubl, D, Albert, PR (2008). Transcriptional regulation at a HTR1A polymorphism associated with mental illness. Neuropharmacology 55, 977–985.CrossRefGoogle Scholar
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM (2009 a). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31–41.CrossRefGoogle ScholarPubMed
Leucht, S, Komossa, K, Rummel-Kluge, C, Corves, C, Hunger, H, Schmid, F, Asenjo Lobos, C, Schwarz, S, Davis, JM (2009 b). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 166, 152–163.CrossRefGoogle ScholarPubMed
Matheson, GK, Pfeifer, DM, Weiberg, MB, Michel, C (1994). The effects of azapirones on serotonin1A neurons of the dorsal raphe. General Pharmacology 25, 675–683.CrossRefGoogle ScholarPubMed
McGrath, PJ, Stewart, JW, Quitkin, FM, Wager, S, Jenkins, SW, Archibald, DG, Stringfellow, JC, Robinson, DS (1994). Gepirone treatment of atypical depression: preliminary evidence of serotonergic involvement. Journal of Clinical Psychopharmacology 14, 347–352.CrossRefGoogle ScholarPubMed
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG; PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. British Medical Journal 339, b2535.CrossRefGoogle ScholarPubMed
Moll, JL, Brown, CS (2011). The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature. Journal of Sexual Medicine 8, 956–970.CrossRefGoogle ScholarPubMed
Montgomery, SA, Asberg, M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382–389.CrossRefGoogle ScholarPubMed
Newman-Tancredi, A, Gavaudan, S, Conte, C, Chaput, C, Touzard, M, Verriele, L, Audinot, V, Millan, M (1998). Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a (35S)GTPgammaS binding study. European Journal of Pharmacology 21, 245–256.CrossRefGoogle Scholar
Newman-Tancredi, A, Kleven, MS (2011). Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berlin) 216, 451–473.CrossRefGoogle ScholarPubMed
Onder, E, Tural, U (2003). Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. Journal of Affective Disorders 76, 223–227.CrossRefGoogle ScholarPubMed
Pinto, C, Souza, RP, Lioult, D, Semeralul, M, Kennedy, JL, Warsh, JJ, Wong, AH, Luca, VD (2011). Parent of origin effect and allelic expression imbalance of the serotonin transporter in bipolar disorder and suicidal behaviour. European Archives of Psychiatry and Clinical Neuroscience 261, 533–538.CrossRefGoogle ScholarPubMed
Pompili, M, Serafini, G, Innamorati, M, Moller-Leimkuhler, AM, Giupponi, G, Girardi, P, Tatarelli, R, Lester, D (2010). The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention. European Archives of Psychiatry and Clinical Neuroscience 260, 583–600.CrossRefGoogle ScholarPubMed
Prins, J, Olivier, B, Korte, SM (2011). Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opinion on Investigational Drugs 20, 1107–1130.CrossRefGoogle ScholarPubMed
Rausch, JL, Ruegg, R, Moeller, FG (1990). Gepirone as a 5-HT1A agonist in the treatment of major depression. Psychopharmacology Bulletin 26, 169–171.Google Scholar
Rickels, K, Amsterdam, J, Clary, C, Hassman, J, London, J, Puzzuoli, G, Schweizer, E (1990). Buspirone in depressed outpatients: a controlled study. Psychopharmacology Bulletin 26, 163–167.Google ScholarPubMed
Rickels, K, Derivan, A, Kunz, N, Pallay, A, Schweizer, E (1996). Zalospirone in major depression: a placebo-controlled multicenter study. Journal of Clinical Psychopharmacology 16, 212–217.CrossRefGoogle ScholarPubMed
Robinson, DS, Sitsen, JM, Gibertini, M (2003). A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone. Clinical Therapeutics 25, 1618–1633.CrossRefGoogle ScholarPubMed
Savitz, J, Lucki, I, Drevets, WC (2009). 5-HT(1A) receptor function in major depressive disorder. Progress in Neurobiology 88, 17–31.CrossRefGoogle ScholarPubMed
Schweizer, E, Rickels, K, Hassman, H, Garcia-Espana, F (1998). Buspirone and imipramine for the treatment of major depression in the elderly. Journal of Clinical Psychiatry 59, 175–183.CrossRefGoogle ScholarPubMed
Stahl, SM, Kaiser, L, Roeschen, J, Keppel Hesselink, JM, Orazem, J (1998). Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. International Journal of Neuropsychopharmacology 1, 11–18.CrossRefGoogle ScholarPubMed
Tanaka, H, Tatsuno, T, Shimizu, H, Hirose, A, Kumasaka, Y, Nakamura, M (1995). Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. General Pharmacology 26, 1765–1772.CrossRefGoogle ScholarPubMed
Tsutsui, S, Saito, T, Katsura, N (1992). Double blind comparative study of tandospirone (SM-3997) on neurosis. Placebo-controlled dose-finding study. Clinical Report 26, 4265–4288.Google Scholar
Whitaker-Azmitia, PM, Druse, M, Walker, P, Lauder, JM (1996). Serotonin as a developmental signal. Behavioural Brain Research 73, 19–29.CrossRefGoogle ScholarPubMed
Wilcox, CS, Ferguson, JM, Dale, JL, Heiser, JF (1996). A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacology Bulletin 32, 335–342.Google ScholarPubMed
Yamada, K, Yagi, G, Kanba, S (2003). Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial. Psychiatry and Clinical Neurosciences 57, 183–187.CrossRefGoogle ScholarPubMed
Zuideveld, K, Rusic-Pavletic, J, Maas, H, Peletier, L, Van der Graaf, P, Danhof, M (2002). Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats. Journal of Pharmacology and Experimental Therapeutics 303, 1130–1137.CrossRefGoogle ScholarPubMed
Supplementary material: File

Kishi et al. Supplementary Material

Tables

Download Kishi et al. Supplementary Material(File)
File 224.8 KB
Supplementary material: File

Kishi et al. Supplementary Material

Figures

Download Kishi et al. Supplementary Material(File)
File 137.7 KB